نتائج البحث - Jan Müller‐Brand

  • يعرض 1 - 14 نتائج من 14
تنقيح النتائج
  1. 1
    Plasma potassium in patients with terminal renal failure during and after haemodialysis; relationship with dialytic potassium removal and total body potassium

    Plasma potassium in patients with terminal renal failure during and after haemodialysis; relationship with dialytic potassium removal and total body potassium حسب A Blumberg, H.W. Roser, C Zehnder, Jan Müller‐Brand

    منشور في 1997
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease

    The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease حسب Martin A. Walter, R Melzer, Christian Schindler, Jan Müller‐Brand, Alan Tyndall, Egbert Nitzsche

    منشور في 2005
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer: Long-Term Results of a Longitudinal Cohort Study

    The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer: Long-Term Results of a Longitudinal Cohort Study حسب Martin A. Walter, Christian P. Turtschi, Christian Schindler, Peter Minnig, Jan Müller‐Brand, Beat P. Müller‐Stich

    منشور في 2007
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    In vitro characterization of 177Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study

    In vitro characterization of 177Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study حسب Flavio Forrer, Jianhua Chen, Melpomeni Fani, P. Powell, Andreas Lohri, Jan Müller‐Brand, Gerhard Moldenhauer, Helmut R. Maëcke

    منشور في 2009
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Somatostatin Receptor–Targeted Radiopeptide Therapy with <sup>90</sup>Y-DOTATOC and <sup>177</sup>Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial

    Somatostatin Receptor–Targeted Radiopeptide Therapy with <sup>90</sup>Y-DOTATOC and <sup>177</sup>Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Tri... حسب Nicolas Marincek, Piotr Radojewski, Rebecca A. Dumont, Philippe Brunner, Jan Müller‐Brand, Helmut R. Maëcke, Matthias Briel, Martin A. Walter

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial

    Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial حسب Dominik Cordier, Flavio Forrer, Frank Bruchertseifer, Alfred Morgenstern, Christos Apostolidis, Stephan Good, Jan Müller‐Brand, Helmut R. Mäcke, J.C. Reubi, Adrian Merlo

    منشور في 2010
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials

    Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials حسب Martin A. Walter, Matthias Briel, Mirjam Christ‐Crain, Steen Joop Bonnema, John Connell, David S. Cooper, Heiner C. Bucher, Jan Müller‐Brand, Beat P. Müller‐Stich

    منشور في 2007
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours

    Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours حسب Anna Romer, Daniela Seiler, Nicolas Marincek, Philippe Brunner, Michael Koller, Quinn K.T. Ng, Helmut R. Maëcke, Jan Müller‐Brand, Christoph Rochlitz, Matthias Briel, Christian Schindler, Martin A. Walter

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Cohort Study of Somatostatin-Based Radiopeptide Therapy With [<sup>90</sup>Y-DOTA]-TOC Versus [<sup>90</sup>Y-DOTA]-TOC Plus [<sup>177</sup>Lu-DOTA]-TOC in Neuroendocrine Cancers

    Cohort Study of Somatostatin-Based Radiopeptide Therapy With [<sup>90</sup>Y-DOTA]-TOC Versus [<sup>90</sup>Y-DOTA]-TOC Plus [<sup>177</sup>Lu-DOTA]-TOC in Neuroendocrine Cancers حسب Linda Villard, Anna Romer, Nicolas Marincek, Philippe Brunner, Michael Koller, Christian Schindler, Quinn K.T. Ng, Helmut R. Mäcke, Jan Müller‐Brand, Christoph Rochlitz, Matthias Briel, Martin A. Walter

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Progression to Overt or Silent CAD in Asymptomatic Patients With Diabetes Mellitus at High Coronary Risk

    Progression to Overt or Silent CAD in Asymptomatic Patients With Diabetes Mellitus at High Coronary Risk حسب Michael J. Zellweger, Michael Maraun, Hans H. Osterhues, Ulrich Keller, Jan Müller‐Brand, Raban Jeger, Otmar Pfister, Thilo Burkard, Friedrich Eckstein, Stefanie von Felten, Stefan Osswald, Matthias Pfisterer

    منشور في 2014
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Procalcitonin levels predict clinical course and progression‐free survival in patients with medullary thyroid cancer

    Procalcitonin levels predict clinical course and progression‐free survival in patients with medullary thyroid cancer حسب Martin A. Walter, Christian Meier, Tanja Radimerski, Fabienne Iten, Marius Kränzlin, Jan Müller‐Brand, Jan Willem B. de Groot, Ido P. Kema, Thera P. Links, Beat P. Müller‐Stich

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors

    Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors حسب Nancy Sharma, Boris G. Naraev, Eric G. Engelman, M. Bridget Zimmerman, David Bushnell, Thomas M. O’Dorisio, M. Sue O’Dorisio, Yusuf Menda, Jan Müller‐Brand, James R. Howe, Þorvarður R. Hálfdánarson

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors

    The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors حسب Philippe Brunner, Ann-Catherine Jörg, Katharina Glatz, Lukas Bubendorf, Piotr Radojewski, M Umlauft, Nicolas Marincek, Petar-Marko Spanjol, Thomas Krause, Rebecca A. Dumont, Helmut R. Maëcke, Jan Müller‐Brand, Matthias Briel, Anja Schmitt, Aurel Perren, Martin A. Walter

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis

    The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis حسب Martin Fuchs, Matthias Briel, Thomas Daikeler, Ulrich A. Walker, Helmut Rasch, Scott Berg, Quinn K.T. Ng, Heike Raatz, David Jayne, Ina Kötter, Daniël Blockmans, María C. Cid, Sergio Prieto‐González, Peter Lamprecht, Carlo Salvarani, Zaharenia Th. Karageorgaki, Richard A. Watts, Raashid Luqmani, Jan Müller‐Brand, Alan Tyndall, Martin A. Walter

    منشور في 2011
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: